Hanmi Pharma says Genentech terminates belvarafenib (HM95573) license, returns rights

• Hanmi Science unit Hanmi Pharmaceutical received Genentech notice ending the belvarafenib (HM95573) licensing deal on Sept. 29, 2026.
• Termination takes effect 90 days from notice, returning rights to Hanmi Pharmaceutical.
• Hanmi Pharmaceutical will keep the upfront payment of USD 80 million already received.
• Both sides plan to work toward a smooth handover through the contract end date of Dec. 27, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hanmi Science Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20260929800995), on September 29, 2026, and is solely responsible for the information contained therein.